Inotiv, Inc.NOTVEarnings & Financial Report

Nasdaq · pharmaceutical industry

Inotiv, Inc. is a contract research organization organized in Indiana and headquartered in Lafayette, Indiana. The company operates two core business units: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The CRS business unit offers drug development and environmental sciences services, including safety assessment, analytical, metabolism, CMC and regulatory consultancy for small molecule drug candidates, biotherapeutics, and biomedical devices. The RMS business u...

Revenue

$120.9M

Gross Profit

N/A

Operating Profit

$-16.3M

Net Profit

$-28.4M

Gross Margin

N/A

Operating Margin

-13.5%

Net Margin

-23.5%

YoY Growth

0.8%

EPS

$-0.83

Financial Flow

Inotiv, Inc. Q1 2026 Financial Summary

Inotiv, Inc. reported revenue of $120.9M for Q1 2026, with a net profit of $-28.4M (-23.5% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue	$120.9M
Net Profit	$-28.4M
Gross Margin	N/A
Operating Margin	-13.5%
Report Period	Q1 2026

Inotiv, Inc. Annual Revenue by Year

Inotiv, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $513.0M).

Year	Annual Revenue
2025	$513.0M
2024	$490.7M
2023	$572.4M
2022	$547.7M

Income Statement

	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$119.0M	$105.8M	$130.4M	$119.9M	$124.3M	$130.7M	$138.1M	$120.9M
YoY Growth	-21.4%	-32.8%	-7.3%	-11.5%	4.4%	23.5%	5.9%	0.8%

Balance Sheet

	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Assets	$815.4M	$774.6M	$781.4M	$772.9M	$766.0M	$759.7M	$771.1M	$734.3M
Liabilities	$608.2M	$592.5M	$610.9M	$603.1M	$608.3M	$616.0M	$635.1M	$625.3M
Equity	$207.2M	$182.1M	$170.5M	$169.8M	$157.7M	$143.8M	$136.0M	$109.0M